Bexxar (Corixa/GlaxoSmithKline).
Bexxar (131I tositumomab) is a radiolabeled anti-CD20 monoclonal antibody for the treatment of relapsed and refractory follicular/low-grade and transformed non-Hodgkin's lymphoma. It has shown high response rates with durable complete remissions in patients who have received either prior chemotherapy or rituximab (Rituxan, MabThera; IDEC Pharmaceuticals Corp/Genentech/F Hoffmann La Roche). Complications include myelosuppression, secondary acute leukemia, myelodysplasia and hypothyroidism. The role of this promising new agent is being defined in phase II and III trials. In February 2001, ABN Amro Predicted launch in 2001 and sales of US $25 million rising to US $70 million in 2003 [422363]. Corixa and GlaxoSmithKline anticipate a launch in the US in 2002 [424619].
Cheson
Bruce
B
Medicine Section, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA. chesonb@ctep.nci.nih.gov
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D013678:Technology, Pharmaceutical / Q000379:methods / Q000706:statistics & numerical data
D000911:Antibodies, Monoclonal; C119496:tositumomab I-131